Method of visualizing a bridge therapy process

• US 9,788,798 B2
• Filed: 06/12/2012
• Issued: 10/17/2017
• Est. Priority Date: 06/16/2011
• Status: Active Grant

• Current Assignee: Koninklijke Philips N.V.
• Original Assignee: Koninklijke Philips N.V.
• Inventors: Van Ooijen, Henk Jan, Van Den Ham, Rene, Bakker, Bart
• Primary Examiner(s): He, Yingchun
• Application Number:
  US14/126,545
• Publication Number:
  US 20140118356A1
• Time in Patent Office: 1,953 Days
• Field of Search: None
• CPC Class Codes: A61B 5/02028 Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction
• CPC Class Codes: A61B 5/02042 Determining blood loss or bleeding, e.g. during a surgical procedure
• CPC Class Codes: A61B 5/026 Measuring blood flow A61B3/1233, A61B3/1241 take precedence
• CPC Class Codes: A61B 5/4848 Monitoring or testing the effects of treatment, e.g. of medication
• CPC Class Codes: A61B 5/7275 Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
• CPC Class Codes: A61B 5/7278 Artificial waveform generation or derivation, e.g. synthesising signals from measured signals A61B5/327 takes precedence
• CPC Class Codes: A61B 5/742 using visual displays A61B5/339 takes precedence
• CPC Class Codes: A61B 5/7475 User input or interface means, e.g. keyboard, pointing device, joystick
• CPC Class Codes: G16B 45/00 ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
• CPC Class Codes: G16B 5/30 Dynamic-time models
• CPC Class Codes: G16H 10/40 for data related to laboratory analysis, e.g. patient specimen analysis
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 40/60 for the operation of medical equipment or devices
• CPC Class Codes: G16H 50/20 for computer-aided diagnosis, e.g. based on medical expert systems
• CPC Class Codes: G16H 50/30 for calculating health indices; for individual health risk assessment
• CPC Class Codes: G16H 50/50 for simulation or modelling of medical disorders

Abstract

The present invention provides for a simultaneous graphical representation, a risk of bleeding and a risk of thrombosis providing a visualized bridge therapy process. Furthermore, the present invention provides for a computer-based prediction of the haemostatic situation of the examined blood circulation by using a combination of a biochemical model and a pharmacokinetic model for calculation or another mathematical representation of the blood circulation.

Claims

1. A method of visualizing a bridge therapy process, the method comprising the steps of:

receiving coagulation data describing a haemostatic situation of a blood circulation of a patient at a computer having a processor and a display, and

displaying, on the display of the computer, the coagulation data to a user by means of a graphical representation, the displaying including;

displaying a first value measured by a first type of blood test, wherein the first value indicates a first effect of a heparin like drug on the haemostatic situation, and

simultaneously to the displaying of the first value displaying a second value measured by a second type of blood test, wherein the second value indicates a second effect of a vitamin K antagonist type anticoagulant on the haemostatic situation, and

wherein the first and second values describe the haemostatic situation of the blood circulation at a first point in time and are simultaneously displayed as a first point within an X and Y coordinate system having the first value for the X axis and the second value for the Y axis.

2. The method according to claim 1, the displaying of the coagulation data further comprising the steps of:

displaying, on the display of the computer, a third value measured by the first type of blood test, wherein the third value indicates a third effect of a heparin like drug on the haemostatic situation,

simultaneously to the displaying of the third value displaying, on the display of the computer, a fourth value measured by the second type of blood test, wherein the fourth value indicates a fourth effect of a vitamin K antagonist type anticoagulant on the haemostatic situation,

wherein the third and fourth values describe the haemostatic situation of the blood circulation at a second point in time and are simultaneously displayed as a second point within the X and Y coordinate system having the third value for the X axis and the fourth value for the Y axis.

3. The method according to claim 1, wherein the first and second type of blood test are respectively and independently chosen from the group consisting of activated partial thrombopiastine time (aPTT) test, anti-Factor 10a test, prothrombin time (PT) test, international normalized ratio (INR) test, a test indicating thrombosis or coagulation, a test indicating bleeding or anti-coagulation, a test indicating the haemostatic function.

4. The method according to claim 1, further comprising the step of:

calculating, using the processor of the computer, a prediction of the haemostatic situation of the blood circulation by a mathematical representation of the blood circulation.

5. The method according to claim 1, further comprising the step of:

calculating, using the processor of the computer, a prediction of the haemostatic situation of the blood circulation by combining a biochemical model of the blood circulation and a pharmacodynaniical model of the blood circulation.

6. The method according to claim 5, further comprising the steps of:

calculating, using the processor of the computer, an effect of an anticoagulant drug during a predetermined time by using the pharmacodynamical model, to generate a calculated pharmacodynamical effect.

7. The method according to claim 6, the method further comprising the steps of:

calculating, using the processor of the computer, a coagulation effect and/or a fibrin polymerization effect with the biochemical model based on the calculated pharmacodynamical effect, and

displaying, on the display of the computer, a prediction value of the haemostatic situation,

wherein the prediction value is based on at least one of the calculated pharmacodynamical effect, the calculated coagulation effect, and the calculated fibrin polymerization effect.

8. The method according to claim 1, the method further comprising the step of:

automatically suggesting an application of a coagulant and/or an anti-coagulant.

9. The method according to claim 8, wherein the step of automatically suggesting an application of a coagulant and/or an anti-coagulant is based on a calculated progression of the haemostatic situation.

10. The method of claim 1 further comprising the step of:

displaying a rectangle in the X and Y coordinate system depicting a region in which a safe haemostatic situation is indicated.

11. A user interface device for visualizing a bridge therapy process, the user interface comprising:

a user interface configured to receive coagulation data describing a haemostatic situation of a blood circulation of a patient,

a display configured to display the haemostatic situation of said blood circulation including;

displaying a first value measured by a first type of blood test, wherein the first value indicates a first effect of a heparin like drug on the haemostatic situation, and

simultaneously displaying a second value measured by a second type of blood test, wherein the second value indicates a second effect of a vitamin K antagonist type anticoagulant on the haemostatic situation;

wherein the first and second values describe the haemostatic situation of the blood circulation at a first point in time; and

wherein the first and second values are simultaneously displayed as the first point within a two-dimensional coordinate system having an axis for the first type of blood test and a different axis for the second type of blood test.

12. The user interface device according to claim 11 wherein the user interface is configured to display a time progression of the haemostatic situation of said blood circulation by further:

displaying a third value measured by the first type of blood test, wherein the third value indicates a third effect of a heparin like drug on the haemostatic situation at a second point in time, and

displaying a fourth value measured by the second type of blood test simultaneously to the first, second and third value, wherein the fourth value indicates a fourth effect of a vitamin K antagonist type anticoagulant on the haemostatic situation at the second point in time, and

wherein the third and fourth values describe the haemostatic situation of the blood circulation at the second point in time.

13. The user interface device according to claim 11, further comprising:

a computer processor configured to calculate a prediction of the haemostatic situation of the blood circulation by using mathematical representation of the blood circulation or by a combining a biochemical model of the blood, circulation and a pharmacodynamical model of the blood circulation.

14. The user interface device according to claim 11, wherein the computer processor is configured to:

calculate an effect of an anticoagulant drug during a predetermined time by using the pharmacodynamical model,

generate a calculated pharmacodynamical effect, and

use the calculated pharmacodynamical effect as an input for the biochemical model.

15. The user interface device of claim 11 wherein the display is configured to further display a rectangle in the two-dimensional coordinate system depicting a region in which a safe haemostatic situation is indicated.

16. A non-transitory computer readable medium in which a program element for visualizing a bridge therapy process is stored, which, when being executed by a computer including a processor and a display performs a method including:

receiving coagulation data describing a haemostatic situation of a blood circulation including at least;

a first value measured at a first point in time by a first type of blood test that indicates an effect of a heparin like drug on the haemostatic situation, and

a second value measured at the first point in time by a second type of blood test that indicates an effect of a vitamin K antagonist type anticoagulant on the haemostatic situation,

displaying, on the display, a two-dimensional coordinate system having a first axis representing the first type of blood test and a second axis representing the second type of blood test, and

plotting a point in the two-dimensional coordinate system representing the effect at the first point in time of both the heparin like drug and the vitamin K antagonist type anticoagulant, the plotted point having the first value on the first axis and the second value on the second axis.